Hubbry Logo
Canopy GrowthCanopy GrowthMain
Open search
Canopy Growth
Community hub
Canopy Growth
logo
7 pages, 0 posts
0 subscribers
Be the first to start a discussion here.
Be the first to start a discussion here.
Canopy Growth
Canopy Growth
Canopy Growth
View on Wikipedia
from Wikipedia

Canopy Growth Corporation, formerly Tweed Marijuana Inc., is a cannabis company based in Smiths Falls, Ontario.

Key Information

In April 2019, Canopy was the world's largest cannabis company based on the value of all shares or market capitalization.[2] At that time, Constellation Brands Inc. controlled over 35% percent of the company which had approximately 3,200 employees.[3] The year 2019 created new challenges for the company however, with its stock price dropping by about 32%.[4] In the next two years (to the end of 2021) its shares dropped an additional 55%. In September 2022, the company announced divestiture of its Canadian retail operations, selling its 28 retails stores across the country to other cannabis companies.[5]

History

[edit]
Tweed branded cannabis as sold in Alberta

Tweed was founded by Bruce Linton and Chuck Rifici[6] in 2013,[7][8] and renamed Canopy Growth Corporation in 2015 after a merger with Bedrocan Canada.

Bruce Linton was the primary Founder, Chairman and Co-CEO[9] and Mark Zekulin was Co-CEO and President until July 3, 2019, when Linton was ousted from the company.[10] Zekulin became the sole CEO, until later that year a new CEO was announced and Zekulin stepped down on 20 December.[11]

Canopy Growth was the first federally regulated, licensed, publicly traded cannabis producer in North America, traded on the Toronto Stock Exchange as WEED. It began trading as CGC on the New York Stock Exchange on May 24, 2018,[12] as the first cannabis producer on the NYSE.[13] On October 17, 2018,[14] marijuana became legal in Canada for recreational use.[15] Canada's first legal cannabis sale was made at midnight by CEO Bruce Linton at a Tweed store in St. John's, Newfoundland and Labrador.[16]

Prior to that date, cannabis was legal only for medical purposes in Canada; growers were licensed by Health Canada under the Access to Cannabis for Medical Purposes Regulations (ACMPR).[17] The company was described as "Canada's first cannabis unicorn with a $1 billion dollar valuation" by the Financial Post news organization in November 2016.[18] The company was renamed to Canopy Growth Corp. in September 2015 with two established brands: Tweed Inc. and Bedrocan Canada Corp.[19] Specifically, CGC is the parent company of licensed cannabis producers Tweed Inc., Tweed Farms Inc., Spectrum Cannabis., as well as newly acquired companies.

Tweed operates out of the former Hershey's chocolate factory in Smiths Falls, Ontario,[20] and operates the Tweed Farms greenhouse in Niagara-on-the-Lake.[21][22]

In provinces where the private sector is allowed to sell cannabis, the company has opened retail stores via its subsidiary Tweed Inc.[15][23][24] As of April 2019, Tweed stores were open in Manitoba, Newfoundland and Labrador, and Saskatchewan.[25] Canopy Growth has opened cannabis stores in Manitoba and Ontario under the Tokyo Smoke brand.[26]

In June 2018, Canopy Growth funded Professorships in Cannabis Science at the University of British Columbia in Vancouver, in conjunction with the British Columbia Centre on Substance Use (BCCSU).[27] By October 5, 2018, the company's market capitalization exceeded US$14 billion[28] and Linton was named 2018 CEO of the Year by the Ottawa Board of Trade and Ottawa Business Journal.[29][30]

Partnership with Constellation Brands

[edit]

In August 2018, Constellation Brands – an American beer, wine and spirits producer with global markets – announced its investment of an additional Can$5 billion (US$3.8 billion) in Canopy Growth, giving it 38% ownership of the company,[3] up from the previous 10%. President Bruce Linton said the additional funds would be used for international expansion wherever federal laws allow it.[31][32] Future marketing plans include products such as cannabis-infused beverages and sleep aids.[33] After the Constellation deal was announced, the market value of Canopy Growth rose to nearly US$12 billion.[34][35] At the end of 2019, when the Canadian cannabis market had declined over the second half of the year, Constellation Brands announced there were no plans to invest further in Canopy Growth, although long-term plans to develop drinkable cannabis products for medical and recreational markets remained in place.[36]

2019 restructuring

[edit]

News reports indicated that Bruce Linton had been ousted from all of his roles with Canopy Growth and Canopy Rivers, its venture capital division, on July 2, 2019, after an emergency board meeting.[36]

This move came a few days after Constellation Brands, which then held four of the seven Canopy board seats and controlled nearly 40% of the firm, expressed dissatisfaction with the cannabis giant's financial results.[36] (By that time, CFO Tim Saunders had been replaced.) Significant losses had been reported during its efforts to increase the size of greenhouse facilities in British Columbia and Quebec. The fourth quarter 2018 loss had been much greater than expected, with a net loss attributable to shareholders of $335.6 million, substantially higher than the net loss that had been predicted by analysts. A CTV News report summarized the situation as: "the cannabis company's expenses ballooned, its net loss widened and medical and recreational sales activity slowed from the previous quarter". Constellation Brands president and CEO Bill Newlands made this comment in late June 2019: "... we continue to aggressively support Canopy on a more focused, long-term strategy to win markets and form factors that matter while paving a clear path to profitability".[37]

The board left Mark Zekulin to continue as sole CEO and a search was to be conducted for a replacement co-CEO. Rade Kovacevic was named President and John Bell was appointed chairman. As of early July 2019, Linton held 18 million shares of Canopy. In an interview, he told CNBC that he had been "terminated", not "stepped down" as previous reports had suggested. "I was asked to leave, and I left under the terms that we mutually agreed to", he explained.[11][38]

A mid-November 2019 report said that the company's stock "slid more than 17% Thursday ... after the company posted weaker-than-expected earnings for its fiscal second quarter".[39] By that time, cannabis stocks in general had "crumbled to their lowest level since 2017" according to an October 2019 report.[40]

On 9 December 2019, the company announced a new CEO, David Klein, previously executive vice president and chief financial officer at Constellation Brands and Canopy Growth's chair. (By that time, Canopy's stock had dropped 32% since the start of 2019). Interim CEO and co-founder Mark Zekulin was to step down before year end; Klein was to assume his new role on 14 January 2020.[4] One news report stated that the appointment of Klein would further entrench Constellation’s influence on Canopy Growth.[41]

In December 2020, the company announced that it will close some sites in Canada which can affect the jobs of 220 employees.[42]

Overseas operations

[edit]

In addition to operations in Canada, Canopy Growth has a partnership agreement in Spain with pharma company Alcaliber S.A.,[43] owns a subsidiary in Germany that imports medical cannabis, Spectrum Therapeutics GmbH,[44] and has a partnership with Spectrum Cannabis Denmark ApS, a medical cannabis grower.[45] The company is also involved in the business in Jamaica, Chile, Peru and Brazil,[46][47][48] as well as in Australia. In 2018, the company acquired Annabis Medical, a distributor in the Czech Republic, and medical marijuana supplier Daddy Cann Lesotho in Africa.[23] In February 2019 Canopy set up a partnership with the Beckley Foundation to distribute medical cannabis in the UK.[49]

Expansion

[edit]

Subsequent acquisitions for this corporation included Vert Medical, the German cannabis distributor MedCann (now Spectrum Therapeutics) and a majority interest in Quebec's Groupe H.E.M.P.CA Inc. In early December 2016, Canopy Growth Corp. announced a friendly takeover bid of another licensed Ontario-based producer, Mettrum Health (CVE:MT). The deal, pending the approval of Mettrum's board, was closed in January 2017.[50]

In addition to sales in the domestic market, Canopy Growth began selling medical cannabis products in Germany and Brazil in 2016. However, the company was operating at a loss, presumably because of the significant expenditures it was making to acquire competitors in preparation for significantly increased cannabis demand by the recreational use market expected to commence in 2018. Legislation to legalize cannabis for recreational use was approved by the House of Commons of Canada in November 2017;[51] the Senate of Canada was expected to vote on the Cannabis Act (Bill C-45) on June 7, 2018.[52] Actual sales to casual users was likely to commence in January 2018.[53][54] In January 2019, Canopy Growth announced that it was granted a license by New York State to process and produce hemp in the United States.[55]

On January 27, 2017, Canopy and Mettrum Health Corp. announced the takeover of Mettrum by Canopy. The deal was awaiting approval by the Ontario Superior Court of Justice. At around the same time the deal had closed, Canopy completed the purchase of the entire former Hershey's chocolate factory, adding 50 percent more production space at that location.[56] The takeover of Mettrum has resulted in "the creation of a world-leading diversified cannabis company with six licensed facilities and a licensed production footprint of approximately 665,000 sq. ft. with significant acreage for expansion".

In February 2018, Canopy Growth Corporation and Sunniva Inc., a North American provider of medical cannabis, announced a supply agreement. Sunniva's Canadian subsidiary, Sunniva Medical Inc., committed to selling Canopy 45,000 kilograms of premium quality cannabis annually for a two-year period commencing in the first quarter of 2019.[57]

Expansion into Europe continued in April 2019 with the acquisition of licensed cannabis producer Cáñamo y Fibras Naturales, S.L. which is based in Spain. By that time, the Company already owned a licensed production site in Odense, Denmark, as well as the Storz and Bickel facility in Tuttlingen, Germany.[58]

A tentative expansion step into the US market was also made in April 2019. The company concluded a deal to pay US$300-million for the right to buy cannabis company Acreage Holdings Inc. a company located in British Columbia but with a diverse portfolio of cannabis cultivation, processing and dispensing operations in the US.[59] No actual purchase was made, but the agreement states that Canopy will buy 100% of Acreage shares for US$3.4 billion if the American federal government legalizes cannabis. In an interview with The Canadian Press, Vivien Azer, senior research analyst with Cowen, said that Acreage was a suitable acquisition target because it had the greatest market penetration in the U.S. and believed that the deal would "likely prove helpful in pushing for a change in U.S. laws surrounding cannabis".[60]

Hiku Brands

[edit]

Hiku was a recreational and medical cannabis company based in Toronto, Ontario and Kelowna, British Columbia which was acquired by Canopy Growth Corp. on July 10, 2018. Hiku's subsidiaries included Tokyo Smoke, DOJA, Van der Pop and Maïtri.[61]

Hiku formed as a result of a merger between DOJA Cannabis Company and Tokyo Smoke in December 2017, and later through the additions of Maitri Group and TS Brandco Holdings. Hiku Brands officially became ‘Tokyo Smoke Brands’ in March 2019.[62] On July 10, 2018, cannabis producer Canopy Growth Corp. announced the acquisition of Hiku Brands Ltd., including their portfolio brands consisting of licensed producer DOJA, women-focused Van der Pop, Quebec-based Maïtri and retail chain Tokyo Smoke.[citation needed]

Hiku Brands (2018)

TS Brandco Holdings Inc (2017)

Maitri Group Inc (2018)

Hiku Brands Company Ltd.

DOJA Cannabis Company (2017)

Tokyo Smoke (2017)

Van der Pop (2017)

Edibles

[edit]

In November 2019, the company announced the release of retail edible cannabis products, including THC- and CBD-infused beverages and chocolates.[63]

References

[edit]
[edit]
Revisions and contributorsEdit on WikipediaRead on Wikipedia

Canopy Growth

View on Grokipedia
from Grokipedia

Canopy Growth Corporation is a Canadian publicly traded engaged in the cultivation, production, distribution, and sale of , , and cannabis-derived products for and recreational purposes. Headquartered in , , the company traces its origins to MABH Ontario Inc., founded in 2010 by Bruce Linton and Chuck Rifici, which evolved into Tweed Marijuana Inc. in 2013 and underwent mergers to form Canopy Growth as one of Canada's first federally licensed producers under the regime. It operates a portfolio of brands offering products such as dried flower, oils, edibles, vapes, and beverages across dried, oil, softgel capsule, and other formats. Following recreational legalization in in 2018, Canopy Growth secured a transformative C$5 billion equity investment from , elevating its ownership stake to approximately 38% and funding aggressive global expansion and acquisitions to establish it as the world's largest company by at the time. However, post-legalization realities—including persistent dominance, regulatory hurdles, product oversupply from overinvestment, and slower-than-expected consumer shift to legal channels—triggered operational strains, repeated restructurings, significant layoffs, asset sales, and a precipitous decline exceeding 99% from peak valuations. In recent years, including fiscal 2025, the company has pursued cost reductions, facility optimizations, and focus on higher-margin segments amid ongoing U.S. market entry efforts via Canopy USA, while facing class-action lawsuits over alleged misleading disclosures related to subsidiary performance and revenue practices.

Company Overview

Founding and Corporate Structure

Canopy Growth Corporation traces its origins to Marijuana Inc., established in 2013 by entrepreneurs Bruce Linton and Chuck Rifici in , , with the aim of producing and distributing under Canada's nascent regulatory framework. The company built on earlier efforts from MABH Ontario Inc., a venture founded by the same individuals in 2010 to explore opportunities in the licensed medical marijuana sector. Tweed secured one of the first producer licenses from on August 8, 2014, enabling it to cultivate and supply legally for medical purposes. In 2014, Marijuana Inc. went public on the , becoming the first federally licensed, publicly traded producer in . This listing facilitated rapid expansion through strategic acquisitions, including the purchase of Farms, which diversified its production capabilities across multiple licensed sites. By 2015, the company restructured as Canopy Growth Corporation following mergers with competitors like Bedrocan Canada, establishing a multi-licensed producer model. Canopy Growth operates as a incorporated under the laws of , , with its headquarters in . It maintains a structure overseeing numerous subsidiaries for cultivation, distribution, and international operations, while being dual-listed on the (TSX: WEED) and (CGC). Ownership is dispersed among institutional investors, with no single entity holding a controlling stake as of recent filings, though historical investments like ' multibillion-dollar infusion in 2018 significantly shaped its capital structure before partial divestments.

Leadership and Governance

Luc Mongeau serves as of Canopy Growth Corporation, having assumed the role effective January 6, 2025, after serving as a board member. Mongeau brings over 25 years of experience in consumer packaged goods, including senior roles at Mars Incorporated and , with a focus on operational efficiency and . His predecessor, David Klein, transitioned to a special advisor role until August 31, 2025, following Klein's tenure since 2020 amid the company's restructuring efforts. Tom Stewart holds the position of , confirmed permanently on September 17, 2025, after serving as interim since July 9, 2025. Stewart, a long-term executive at Canopy, succeeded Judy Hong, who departed after contributing to cost-reduction initiatives during her term from April 2022. Other key executives include Christelle Gedeon as Chief Legal Officer, overseeing legal, regulatory, and government relations functions; Jenny Brewer as ; and Andrew Bevan as Senior of . The is chaired by David Lazzarato, who also serves on the and , Compensation, and Nominating (CGCN) Committee. Lazzarato, appointed in 2016, has extensive experience in finance and governance from prior CEO roles at organizations like . Other directors include Terry Yanofsky, chair of the CGCN Committee, and additional members focused on audit and compensation oversight. The board maintains a committee structure comprising the for financial reporting and internal controls, and the CGCN Committee for director nominations, , and governance policies. As a publicly traded entity listed on the and , Canopy Growth adheres to standard practices, including annual shareholder meetings and proxy disclosures for director elections and auditor appointments. The company's framework emphasizes in the regulated sector, with board mandates requiring independence for key committees and alignment with shareholder interests through performance-based incentives.

Historical Development

Early Operations and Pre-Legalization Growth (2013–2018)

Tweed Marijuana Inc., the precursor to Canopy Growth, was established in 2013 by Bruce Linton and Chuck Rifici in , , focusing on the production and supply of compliant with Canada's Marihuana for Medical Purposes Regulations (MMPR). The company secured one of the initial federal licenses under the MMPR framework, enabling legal cultivation and distribution to authorized patients. In April 2014, Tweed listed on the under the ticker TWMJ, marking it as one of the first publicly traded producers in . Commercial sales commenced the following month, with initial output from its facility emphasizing standardized, pharmaceutical-grade dried . Early operations prioritized scaling cultivation to meet growing demand in the medical sector, where patient numbers under the MMPR rose from approximately 10,000 in 2014 to over 100,000 by 2017, driving sector-wide expansion. Growth accelerated through strategic acquisitions to consolidate and diversify production. In 2014, acquired a major operation rebranded as Farms in , establishing the company as 's first multi-site licensed producer and boosting geographic diversity. The 2015 acquisition of Bedrocan , a producer of EU-GMP certified strains, led to the corporate as Canopy Growth and integrated advanced genetic varieties into its offerings. This was followed by the January 2017 purchase of Mettrum Health Corp. for approximately 0.7132 Canopy shares per Mettrum share, adding patient distribution networks and further production assets. Pre-legalization expansion emphasized infrastructure buildout to capitalize on anticipated recreational reforms signaled by federal policy shifts in 2015–2017. By the end of fiscal (March 31, 2018), Canopy Growth operated multiple sites with over 2.4 million square feet of production capacity, including more than 500,000 square feet of (GMP)-certified space, positioning it as a dominant player in Canada's ahead of recreational on , . This period's growth, from modest medical sales in 2014 to C$94 million in Q4 fiscal , reflected and capacity investments, though profitability remained elusive due to high capital expenditures.

Post-Legalization Expansion and Peak Valuation (2018–2019)

Following the federal legalization of recreational cannabis in Canada on October 17, 2018, Canopy Growth rapidly scaled its operations to capitalize on the newly accessible market, expanding cultivation capacity to approximately 5.6 million square feet across 10 facilities and enhancing its headquarters campus in Smiths Falls, Ontario, to over 950,000 square feet for production and logistics. This buildup included investments in value-added processing and distribution infrastructure to support surging demand, with the company reporting $140.5 million in gross revenue from the recreational channel in fiscal year 2019 (ended March 31, 2019). Financial performance reflected the post-legalization boom, as net revenue for fiscal climbed 191% year-over-year to $226.3 million, with fourth-quarter net revenue alone reaching $94.1 million compared to $22.8 million in the prior year's equivalent period, primarily driven by recreational sales volumes. The influx of capital from ' August 2018 investment—initially $153 million with commitments scaling to approximately $4 billion for a nearly 38% stake—further fueled expansion into branded products and international medical markets, including licensing deals in countries like and . Market enthusiasm peaked amid these developments, with Canopy Growth's shares closing at a record $568.90 on October 15, 2018, just prior to legalization, contributing to a year-end 2018 market capitalization of $9.21 billion; the stock rose an additional 58% in early 2019 before broader sector pressures emerged. Strategic moves, such as the April 2019 agreement granting an option to acquire U.S.-based Acreage Holdings for up to $3.4 billion upon U.S. federal legalization, amplified investor optimism and sustained high valuations through mid-2019, despite ongoing operational losses from aggressive scaling. Acquisition-related expenses totaled $23.4 million in fiscal 2019, underscoring multiple deals to bolster supply chain and brand portfolio.

Restructuring and Contraction (2019–2023)

Following the peak valuation in 2019, Canopy Growth initiated restructuring efforts amid mounting operational losses and cash burn exacerbated by post-legalization market realities in , including oversupply, delayed retail rollout, and persistent competition from the illicit sector. On July 3, 2019, co-CEO Bruce Linton stepped down from his executive and board roles, leaving Mark Zekulin as sole CEO, a move aimed at streamlining leadership to navigate these challenges. The company reported substantial net losses in fiscal 2019, totaling CAD 1.4 billion, driven by impairment charges on overvalued assets and high expansion costs. Subsequent years saw intensified cost-cutting, including workforce reductions and facility optimizations. Canopy implemented phased layoffs, with actions in and early 2023 contributing to cumulative staff cuts exceeding 50% from prior peaks, as the firm grappled with unprofitable operations and pressures. Credit ratings deteriorated sharply, with Fitch assigning a 'C' rating in July citing distressed exchanges and needs projected to yield CAD 100-150 million in annual savings, while S&P downgraded to 'CC' in November amid ongoing liquidity strains. Fiscal 2023 marked a pivotal contraction phase, with net revenue declining 21% year-over-year to $403 million, adjusted for prior divestitures, reflecting reduced volumes and pressures from black-market . On , 2023, Canopy announced the elimination of 800 positions—approximately 35% of its workforce—and the closure of key sites, including its flagship 1 Hershey Drive facility in , , as part of a broader "light asset" transformation to slash operating expenses. These measures, the second major round within 12 months, targeted annual cost reductions of $240-310 million by fiscal 2024's end, alongside exits from unprofitable international markets and divestiture of its Canadian retail chain. Asset sales accelerated to bolster liquidity, with five facilities divested by June 2023 for CAD 81 million in proceeds, part of a program aiming for up to CAD 150 million total by September 2023. In December 2023, the company executed a 1-for-10 share consolidation to meet exchange listing requirements, effective December 15, underscoring ongoing efforts to stabilize its balance sheet amid protracted unprofitability. These steps reflected a shift from aggressive global expansion to domestic focus and efficiency, though analysts noted persistent risks from regulatory delays and market saturation.

Business Operations

Canadian Market Activities

Canopy Growth Corporation's Canadian market activities center on the cultivation, processing, distribution, and wholesale sale of products for and adult-use consumption, following the of recreational in October 2018. The company's segment encompasses operations compliant with federal and provincial regulations, emphasizing high-volume production and supply to licensed retailers and channels rather than retail. In September 2022, Canopy Growth announced the divestiture of its Canadian retail operations to streamline focus on production and B2B distribution, selling stores operating under the and Tokyo Smoke brands. This included agreements with OEG Retail Cannabis for 23 locations across , , and , with the transaction completing in January 2023. The move allowed reallocation of resources toward wholesale partnerships and medical sales, amid broader efforts to address operational inefficiencies in the fragmented provincial retail landscape. The brand remains a for adult-use products, including dried flower, pre-rolls, and vapes, distributed through provincial liquor boards and private retailers. sales, targeted at patients via licensed producers' platforms, have driven segment stability, with the business achieving five consecutive quarters of growth by the end of fiscal 2024. Financial performance in reflected recovery trends into 2025. For the fourth quarter of fiscal 2025 (ended March 31, 2025), cannabis net revenue totaled $40 million, up 4% year-over-year, propelled by 13% growth in medical sales despite softer adult-use volumes. In the first quarter of fiscal 2026 (ended June 30, 2025), adult-use net revenue surged 43% to $27 million, fueled by broader distribution reach and heightened consumer demand for value-oriented products. These gains occurred against a backdrop of industry-wide price compression and , underscoring Canopy Growth's pivot to cost-efficient scaling in medical and wholesale channels.

International and Overseas Ventures

Canopy Growth has pursued international expansion primarily in markets, with principal operations in and as of 2025. The company's international revenue reached $41.3 million in fiscal 2024, up from $38.9 million the prior year, reflecting modest growth amid regulatory developments. In , Canopy Growth has focused on following cannabis legalization on April 1, 2024, which created opportunities for medical market entry. On February 27, 2025, the company launched its brand in the German medical sector, introducing four strains cultivated under an agreement with Portugal-based Gro-Vida, including the Glitter Bomb strain debuted in December 2024. Earlier efforts included partnerships in with Alcaliber S.A. for pharmaceutical-grade production and operations in . To support European growth, Canopy Growth appointed Miles Worne as Managing Director for the region in 2025. In , Canopy Growth expanded its medical portfolio on August 5, 2025, by launching the 7ACRES brand to serve patients in the growing therapeutic market. The company previously held a minority stake in an Australian grower to facilitate supply. Earlier international initiatives included a 2019 multi-year agreement with Colombia-based Procaps for global development, though subsequent in 2020 streamlined operations to better align supply with demand across overseas markets. These efforts have emphasized over recreational, adapting to varying regulatory landscapes while prioritizing high-quality, EU-GMP compliant production.

Product Portfolio and Diversification Efforts

Canopy Growth's product portfolio primarily consists of cannabis-based offerings, including dried flower, pre-rolls, vapes, oils, edibles, and capsules, marketed through distinct recreational and medical brands. Recreational brands such as , DOJA, 7ACRES, Deep Space, and Claybourne target adult-use consumers in with high-THC flower, infused pre-rolls, and vape products designed for specific effects like relaxation or . Medical cannabis products, distributed via Therapeutics, include curated strains and formats for therapeutic use, with expansions into global markets emphasizing strain-specific benefits for conditions like pain and . Complementary offerings encompass vaporizers under & Bickel, gummies from Wana Brands, and topicals like LivRelief, providing non-combustion consumption options and delivery beyond . The company has pursued diversification through product format innovation and international medical cannabis penetration rather than venturing extensively beyond core cannabinoid products. In May 2025, Canopy Growth launched new vapes using CCELL all-in-one technology under Tweed and 7ACRES, alongside high-THC flower, infused pre-rolls, and edibles to capture demand in Canada's adult-use market. July 2025 saw the introduction of Deep Space Infused pre-rolls exceeding 60% THC via liquid diamonds and THCA, available in flavors like Milky Way Melon to appeal to potency-seeking consumers. These efforts align with a strategic pivot to high-margin segments, as articulated in the company's FY2025 results, where international medical revenue reached $40 million, bolstered by portfolio expansions in Germany and Portugal-sourced strains like Tweed Glitter Bomb. Diversification attempts beyond traditional have largely contracted in recent years, with emphasizing a "pure-play " focus to achieve profitability amid prior losses from non-core ventures like beverages and hemp-derived products. In August 2025, the launch of 7ACRES in complemented existing medical brands, targeting regulated export markets without diluting domestic operations. October 2025 initiatives included dedicating the DOJA facility exclusively to craft for Spectrum Therapeutics patients, enhancing efficiency for small-batch, region-specific cultivation. This refocused approach, detailed in investor communications, prioritizes asset-light models and consumer-centric brands over broad non-cannabis expansion, reflecting lessons from earlier over-diversification that strained resources.

Strategic Partnerships and Acquisitions

Investment from Constellation Brands

In October 2017, Constellation Brands announced an initial strategic investment of approximately C$245 million in Canopy Growth Corporation, acquiring a 9.9% ownership stake through the purchase of common shares, along with warrants exercisable for additional shares representing up to 20.4% economic ownership upon full exercise. This deal positioned Constellation as Canopy's largest shareholder at the time and included collaboration on cannabis-infused beverage development, leveraging Constellation's expertise in alcoholic beverages like Corona and Modelo. On August 15, 2018, Constellation committed to a substantially larger of C$5 billion (approximately $3.8 billion at prevailing exchange rates), structured as the purchase of 95.6 million new common shares at C$52.50 per share—a 37.9% premium to Canopy's five-day —and warrants for up to 33.8 million additional shares. The transaction, which closed on November 1, 2018, following shareholder approval and Canadian government review under the Investment Canada Act, increased Constellation's ownership to approximately 38% of Canopy's diluted shares outstanding. It also established a for global beverage innovation, with Constellation gaining board representation and rights to influence product commercialization outside . Subsequent adjustments included a 2019 agreement modifying warrant terms, allowing Constellation to acquire up to 20 million Canopy shares in the before exercise and providing anti-dilution protections. By April 2024, Constellation converted its common shares and a into exchangeable shares of Canopy Growth, reducing its voting influence while maintaining economic exposure, and exited the Canopy board amid U.S. regulatory constraints on investments. As of September 2025, Constellation's stake stood at approximately 18.8%, reflecting dilutions from Canopy's capital raises and share issuances.

Key Acquisitions and Divestitures

In April 2019, Canopy Growth announced an option agreement to acquire Acreage Holdings, a U.S. multi-state operator, for up to $3.4 billion contingent on U.S. federal rescheduling or legalization; the option was exercised by Canopy USA in May 2024 and closed on December 9, 2024, enabling in key U.S. markets. In May 2019, the company acquired C3 Compound Co., a German producer of extracts, from Bionorica for 226 million euros ($253 million), bolstering its European supply chain. In October 2021, Canopy Growth secured options to acquire Wana Brands, a leading U.S. edibles producer, for $298 million and , a vaporizer firm; these were exercised by Canopy USA on May 7, 2024, with Wana's acquisition closing on October 9, 2024, and approximately 77% of Jetty acquired around the same period to expand branded product offerings in edibles and extracts. In April 2021, it completed the acquisition of Supreme Cannabis for CAD 345 million, enhancing its premium flower brands like 7ACRES in the Canadian market. Amid post-2019 operational restructuring, Canopy Growth divested non-core assets to improve liquidity and focus on cannabis operations. On September 27, 2022, it announced the sale of its Canadian retail network, including Tweed and Tokyo Smoke stores outside Alberta, to OEG Inc. and others, completing the transactions on January 3, 2023, to exit direct retail amid competitive pressures. In 2023, the company sold multiple facilities, including five sites generating CAD 81 million in proceeds by June 29 and the Hershey Drive facility to Hershey Canada for undisclosed cash on October 2, targeting up to CAD 150 million total from such sales by September 30 to reduce overhead. On December 18, 2023, it divested its This Works skincare brand to Inspirit Capital, streamlining away from wellness diversification.

Financial Performance

Canopy Growth's revenue grew significantly following the October 2018 legalization of recreational cannabis in Canada, reaching approximately $414 million USD in fiscal year 2021 (ended March 31, 2021), driven by expansion in adult-use sales and international ventures. However, revenue peaked at $415 million USD in fiscal year 2022 before contracting sharply, falling to $305 million USD in fiscal year 2023, $220 million USD in fiscal year 2024, and $193 million USD in fiscal year 2025, reflecting market saturation, price compression from oversupply, and divestitures of underperforming assets. In Canada, the core market, adult-use net revenue declined from $229.6 million CAD in fiscal year 2021 to $205.3 million CAD in fiscal year 2022, with further erosion due to competitive pressures and regulatory constraints on production and distribution. Profitability has remained elusive, with the company posting net losses annually since , totaling over $6 billion USD cumulatively through 2025, exacerbated by goodwill impairments, high selling, general, and administrative expenses, and inefficient capital allocation from aggressive acquisitions. 2023 saw an outsized $2.5 billion USD loss, largely from asset write-downs amid overexpansion. Even as revenue stabilized in recent quarters—such as a 4% year-over-year increase in Canadian revenue to close 2025—operating losses persisted at $18 million CAD in the fourth quarter, though improved 83% from the prior year through cost reductions and gross margin expansion to 35% in the first quarter of 2025. Key challenges include structural issues in the market, where commoditized flower has squeezed margins, and limited international due to regulatory delays in and the U.S., contributing to negative gross profit margins as low as -79% in some quarters. Efforts to mitigate losses, such as divesting non-core businesses (boosting adjusted growth excluding divestitures) and reduction by $293 million CAD (49%) in fiscal year 2025, have shown modest progress, but pretax profit margins remained at -377.7% as of October 2025, underscoring ongoing cash burn and dependency on equity raises.
Fiscal YearRevenue (USD millions)Net Loss (USD millions)
2021414-1,266
2022415-256
2023305-2,504
2024220-359
2025193-434

Stock Market Trajectory and Capital Raises

Canopy Growth Corporation's shares, traded under the ticker CGC on the and WEED on the , experienced a dramatic surge following its on the in 2014 and subsequent uplisting to the TSX in 2016. The stock's price accelerated sharply in 2018 amid hype and a major investment from , reaching an all-time high closing price of $568.90 USD (split-adjusted) on , 2018. Post-peak, the stock entered a prolonged decline, dropping over 99% from its 2018 high by 2025, driven by persistent losses, high cash burn rates, and failure to achieve profitability in competitive markets. By April 8, 2025, shares hit a record low of $0.83 USD, reflecting ongoing operational challenges and investor skepticism about the sector's growth prospects. Annual returns underscored the downturn: -73.54% in 2022, -77.88% in 2023, -46.38% in 2024, and -50.73% year-to-date through October 2025, with the stock closing at $1.35 USD on October 24, 2025. Capital raises have been central to Canopy Growth's financing strategy, often involving equity dilutions and instruments to fund expansion amid revenue shortfalls. In August 2018, invested approximately $4 billion USD through a combination of convertible debentures and shares, providing immediate proceeds of about $5 billion CAD and establishing strategic alignment in the beverage space. Subsequent efforts included a $2 billion CAD shelf prospectus filing in February 2021 to enable flexible equity offerings as reserves dwindled from prior highs of CA$4.1 billion in 2018 to CA$825 million by 2020. In March 2021, the company secured a , with potential for an additional US$250 million, to bolster liquidity. More recently, in May 2024, Canopy Growth announced a financing package yielding approximately US$50 million in gross proceeds while exchanging C$27.5 million of maturing , aimed at strengthening the balance sheet. By 2025, efforts shifted toward reduction, including agreements for three prepayments totaling US$50 million on a —US$25 million paid on July 31 and another US$25 million on September 15—reducing annual cash interest expenses by $6.5 million and signaling a focus on cost management over new raises. These repeated financings have contributed to substantial shareholder dilution, with increasing significantly over the past five years, further pressuring stock value.

Recent Fiscal Developments (2024–2026)

In 2025, ending March 31, 2025, Canopy Growth reported consolidated net revenue of approximately CAD 260 million, reflecting ongoing challenges from divested businesses and competitive pressures in the cannabis market, though adjusted gross margins improved to around 25% from prior years due to cost optimization efforts. The company continued to post net losses, with an adjusted EBITDA loss narrowing sequentially in later quarters amid restructuring, including workforce reductions and facility closures aimed at achieving positive . For the first quarter of FY2025 (April-June 2024), net revenue declined 13% year-over-year to CAD 66 million, primarily from lower Canadian recreational sales, but gross profit rose 67% to CAD 23 million, expanding the gross margin to 35% from 18%, driven by higher-margin and & Bickel vaporizer sales. In Q2 FY2025 (July-September 2024), net revenue fell 9% to CAD 63 million (or rose 3% excluding divested units), with cannabis revenue down 8% but international markets up 12%, particularly in Poland and ; & Bickel revenue grew 32%. Q3 FY2025 (October-December 2024) saw net revenue decrease 5%, offset partially by gains, while Q4 (January-March 2025) dropped 11%, reflecting seasonal softness and divestiture impacts. Entering calendar 2025, Canopy Growth launched a US$200 million at-the-market equity program on August 29 to bolster liquidity and fund U.S. expansion preparations via Canopy USA, amid cash burn concerns. In Q1 FY2026 (April-June 2025), net revenue increased 9% to around US$72 million versus Q1 FY2025, with cannabis segment revenue up 24% from medical and adult-use gains in Canada; however, adjusted EBITDA losses persisted at about CAD 8 million due to operational investments. For Q3 FY2026 (October-December 2025), the company reported consolidated net revenue of $75 million (flat year-over-year), cannabis net revenue of $52 million (+4% YoY), Canada medical cannabis net revenue of $23 million (+15% YoY), and Canada adult-use cannabis net revenue of $23 million (+8% YoY); the net loss narrowed to $62.6 million (-49% YoY), and adjusted EBITDA loss narrowed to $2.9 million (-17% YoY). As of December 31, 2025, Canopy Growth held $371 million in cash and cash equivalents, with a net cash position of $146 million, following a strategic recapitalization in January 2026 that extended debt maturities to 2031. Management highlighted improved fundamentals and cost savings, expressing confidence in achieving positive adjusted EBITDA in fiscal 2027, alongside the pending acquisition of MTL Cannabis. These developments highlight a shift toward profitability through margin expansion and non-cannabis diversification, though sustained revenue growth remains contingent on regulatory progress in key markets.

Controversies and Criticisms

Securities and Accounting Irregularities

In May 2023, Canopy Growth Corporation disclosed material misstatements in its previously issued financial statements for fiscal years 2021 and 2022, as well as certain interim periods, primarily stemming from errors in accounting for its BioSteel subsidiary's sales transactions, revenue recognition, and costs of goods sold. The company attributed these issues to a review uncovering improper revenue deferrals and overstatements, leading to a restatement filed in its Form 10-K for the fiscal year ended March 31, 2023, which adjusted prior-period net losses upward by approximately C$20 million for FY2022. Canopy's audit committee determined the errors were not the result of fraud but required correction under accounting standards codification, prompting the restatement of consolidated financial statements to reflect accurate goodwill impairment, inventory valuations, and other adjustments. Earlier, in February 2019, Canopy Growth identified a formula error that underreported its year-to-date adjusted EBITDA loss by C$27.6 million for the third quarter of fiscal 2019, which it corrected in subsequent disclosures without impacting or cash flows but highlighting weaknesses in financial reporting processes. These disclosures have fueled multiple securities lawsuits alleging violations of federal securities laws through materially false and misleading statements about the company's business, operations, and financial results. For instance, a 2022 settlement resolved claims that Canopy overstated the strength of the Canadian recreational market, resulting in a C$13 million payment to affected investors who purchased securities between June 27, 2018, and February 28, 2019. More recently, in April 2025, plaintiffs filed suits claiming Canopy concealed adverse facts about its performance, including in relation to BioSteel, though a U.S. District Court dismissed one such action in July 2024 for failing to adequately plead or materiality under the Private Securities Litigation Reform Act. Ongoing cases as of June 2025 seek lead plaintiff status for investors alleging similar misrepresentations tied to quarterly earnings misses. No regulatory findings of intentional fraud have been issued by bodies such as the U.S. Securities and Exchange Commission or Canadian Securities Administrators, with the company's whistleblower policy emphasizing anonymous reporting of potential irregularities to mitigate such risks. Canopy Growth operates in a highly regulated , where compliance with evolving government regulations poses significant risks to its licenses and operations. In , the company relies on licenses issued by under the Cannabis Act for production, distribution, and sale; revocation or suspension of these licenses due to non-compliance could halt operations and result in substantial fines. The firm has disclosed 25 legal and regulatory risk factors in recent reports, with 17 specifically tied to regulatory changes that could adversely affect its , including shifts in classification or enforcement priorities. Historical compliance issues underscore these vulnerabilities. In 2018, identified Canopy Growth among licensed producers for "critical" regulatory breaches related to production and security standards, prompting corrective actions but highlighting enforcement risks in a nascent market. Additionally, a subsidiary faced a CA$434,611 penalty from the in 2020 for unauthorized outdoor prior to obtaining full licensure in 2019; the company appealed the fine, arguing it was disproportionately large compared to other penalties. Such incidents illustrate the potential for regulatory scrutiny to impose financial and operational burdens, particularly as competitors engaging in unregulated practices erode licensed producers' market share. Expansion into the U.S. amplifies these risks due to federal prohibition under the , despite state-level legalization. Canopy Growth's Canopy USA entity holds non-controlling stakes in U.S. assets, with options to acquire full control of entities like Acreage Holdings contingent on federal rescheduling of from Schedule I— a process delayed and uncertain as of 2025. Failure to achieve rescheduling could limit access to the lucrative U.S. market, expose investments to forfeiture, and complicate banking and capital access under federal anti-money laundering rules. International regulatory hurdles, including export approvals and varying country-specific prohibitions, further constrain growth, as evidenced by the company's need for ongoing authorizations for cross-border shipments. Legal risks extend beyond regulations to potential litigation from compliance failures or market dynamics. While securities-related claims are distinct, regulatory non-adherence has historically triggered penalties and appeals, straining resources amid ongoing fiscal pressures. The company's filings emphasize that adverse regulatory outcomes, including fines up to CA$1 million per violation for issues like pesticide use, could materially impair viability, especially given its dependence on cannabis-derived revenue.

Market and Operational Critiques

Canopy Growth has faced persistent market critiques for its inability to effectively capture share from Canada's dominant illicit sector following recreational in 2018. Despite initial ambitions to convert consumers, the legal market remains underdeveloped, with illicit sales comprising a significant portion—estimated at over 40% in key provinces like as of 2022—due to high taxes, regulatory restrictions on , and pricing disparities that favor unregulated suppliers. This has resulted in compressed margins for legal producers like Canopy, exacerbating revenue declines, with trailing twelve-month sales dropping 9.5% year-over-year to $201.6 million as of fiscal 2024. Intensified competition from peers such as and emerging low-cost entrants has further eroded Canopy's positioning, prompting analyst concerns over its diminished market influence amid sector consolidation. Operationally, Canopy Growth's aggressive pre-legalization expansion strategy led to chronic overcapacity and excess , culminating in substantial asset impairments and production inefficiencies. The company shuttered multiple facilities and abandoned outdoor cultivation in 2020 amid over CA$1.5 billion in quarterly losses, reflecting misjudged demand forecasts that saddled it with underutilized . write-downs, such as those impacting gross margins negatively by 54% in fiscal Q2 2022, underscored mismatches and high cultivation costs relative to achievable yields. Historical in operations necessitated over 800 job cuts in by early 2023 and further headcount reductions, signaling prior overstaffing and inefficient resource allocation that contributed to a $604 million net loss in fiscal 2025. While recent cost-cutting has trimmed expenses and improved adjusted EBITDA by 61% year-over-year in Q3 2025, ongoing negative highlights lingering issues in transitioning to profitable U.S.-focused operations.

References

  1. https://finance.yahoo.com/quote/CGC/profile/
  2. https://thecanadianencyclopedia.ca/en/article/canopy-growth-corporation
  3. https://pitchbook.com/profiles/company/59682-52
  4. https://www.globaldata.com/company-profile/canopy-growth-corp/
  5. https://ir.cbrands.com/news-events/press-releases/detail/103/constellation-brands-to-invest-5-billion-cad-4-billion-usd-in-canopy-growth-to-establish-transformative-global-position-and-alignment
  6. https://ca.finance.yahoo.com/news/down-incredible-99-time-highs-010000912.html
  7. https://www.bbc.com/news/world-us-canada-67126243
  8. https://www.canopygrowth.com/investors/news-releases/canopy-growth-reports-fourth-quarter-and-fiscal-year-2025-financial-results/
  9. https://www.ainvest.com/chat/share/canopy-growths-accounting-scandal-resurfacedis-cannabis-stock-radioactive-a-contrarian-steal-bf8717/
  10. https://www.theglobeandmail.com/business/article-canopy-growth-cannabis-investors/
  11. https://www.canopygrowth.com/wp-content/uploads/2017/11/Canopy-Growth-Corporation_Q2-2016_MDA.pdf
  12. https://www.newcannabisventures.com/canopy-growth-to-become-first-cannabis-company-to-list-on-toronto-stock-exchange/
  13. https://www.cbinsights.com/company/canopy-growth
  14. https://fintel.io/so/us/cgc
  15. https://www.marketscreener.com/quote/stock/CANOPY-GROWTH-CORP-24025906/company-shareholders/
  16. https://www.canopygrowth.com/investors/news-releases/canopy-growth-announces-mr-luc-mongeau-as-the-companys-next-ceo/
  17. https://www.canopygrowth.com/about/leadership-team/luc-mongeau/
  18. https://www.sec.gov/Archives/edgar/data/1737927/000110465924123094/tm2429555d1_8k.htm
  19. https://www.canopygrowth.com/investors/news-releases/canopy-growth-appoints-tom-stewart-as-chief-financial-officer/
  20. https://www.canopygrowth.com/investors/news-releases/canopy-growth-appoints-tom-stewart-as-interim-chief-financial-officer/
  21. https://www.canopygrowth.com/about/leadership-team/christelle-gedeon/
  22. https://www.canopygrowth.com/about/leadership-team/
  23. https://www.canopygrowth.com/investors/governance/board-of-directors/
  24. https://www.canopygrowth.com/investors/governance/committees-charters/board-directors-mandate/
  25. https://www.canopygrowth.com/investors/governance/committees-charters/corporate-governance-compensation-and-nominating-committee-mandate/
  26. https://www.canopygrowth.com/wp-content/uploads/2023/06/2023.06.15-CGC-CGCN-Committee-Charter.pdf
  27. https://poweronecapital.com/issuer/tweed-marijuana-inc/
  28. https://obj.ca/high-hopes-qa-with-tweed-marijuana-co-founder-bruce-linton/
  29. https://www.ironfx.com/en/canopy-growth-a-look-at-the-companys-history-and-future/
  30. https://www.canopygrowth.com/wp-content/uploads/2018/02/Canopy-Growth-Corporation_Q2_2018_MDA_FINAL.pdf
  31. https://www.canopygrowth.com/wp-content/uploads/2017/07/Canopy_Growth_Corporation_Q3_17_MDA_December_31_2016_FINAL.pdf
  32. https://www.canopygrowth.com/wp-content/uploads/2018/06/180627-Canopy-Growth-Reports-Fourth-Quarter-and-Fiscal-Year-2018-Financial-Results_FINAL.pdf
  33. https://www.newcannabisventures.com/canopy-growth-reports-q4-revenue-of-94-million/
  34. https://thedeepdive.ca/the-rise-and-fall-of-canopy-growth/
  35. https://www.canopygrowth.com/wp-content/uploads/2019/06/190616-Q4-FY-2019-Earnings-Final.pdf
  36. https://www.sec.gov/Archives/edgar/data/1737927/000156459019023506/cgc-ex993_14.htm
  37. https://www.macrotrends.net/stocks/charts/CGC/canopy-growth/stock-price-history
  38. https://companiesmarketcap.com/canopy-growth/marketcap/
  39. https://finance.yahoo.com/news/why-canopy-growth-stock-soared-151200541.html
  40. https://www.canopygrowth.com/investors/news-releases/canopy-growth-announces-plan-to-acquire-acreage-holdings/
  41. https://www.fool.com/investing/2019/08/08/the-5-biggest-marijuana-deals-in-history.aspx
  42. https://www.prnewswire.com/news-releases/canopy-growth-announces-leadership-transition-300879815.html
  43. https://www.canopygrowth.com/wp-content/uploads/2023/08/Canopy-Growth-Annual-Report-2023.pdf
  44. https://globalcannabistimes.com/canopy-growth-slashes-workplace-by-60-in-light-asset-transformation-plan/
  45. https://www.fitchratings.com/research/corporate-finance/fitch-downgrades-canopy-growth-corporation-to-c-on-distressed-debt-exchange-05-07-2022
  46. https://www.spglobal.com/ratings/en/regulatory/article/-/view/type/HTML/id/2911609
  47. https://www.prnewswire.com/news-releases/canopy-growth-reports-fourth-quarter-and-fiscal-year-2023-financial-results-301858576.html
  48. https://financialpost.com/cannabis/cannabis-business/canopy-growth-layoffs-close-facilities
  49. https://www.reuters.com/business/canopy-growth-posts-bigger-quarterly-loss-plans-more-layoffs-2023-02-09/
  50. https://www.canopygrowth.com/investors/news-releases/canopy-growth-reports-fourth-quarter-and-fiscal-year-2023-financial-results/
  51. https://www.canopygrowth.com/investors/news-releases/canopy-growth-announces-facility-sale-and-provides-update-on-divestiture-actions/
  52. https://www.canopygrowth.com/investors/news-releases/canopy-growth-announces-effective-date-of-share-consolidation/
  53. https://www.sedarplus.ca/csa-party/records/document.html?id=6fdfaae7c1127e45616f277b5b1715f8dc6dc3c4281aec362422f761c044b1da
  54. https://www.canopygrowth.com/investors/news-releases/canopy-growth-announces-divestiture-of-canadian-retail-operations/
  55. https://www.canopygrowth.com/investors/news-releases/canopy-growth-completes-divestiture-of-canadian-retail-operations/
  56. https://www.newcannabisventures.com/canopy-growth-exits-canadian-cannabis-store-operations/
  57. https://www.canopygrowth.com/wp-content/uploads/2024/08/Canopy-Growth-Annual-Report-2024.pdf
  58. https://finance.yahoo.com/news/canopy-growth-reports-fourth-quarter-110000629.html
  59. https://www.canopygrowth.com/investors/news-releases/canopy-growth-reports-first-quarter-fiscal-2026-financial-results/
  60. https://finance.yahoo.com/news/canopy-growth-reports-first-quarter-110000652.html
  61. https://www.canopygrowth.com/investors/news-releases/canopy-growth-establishes-new-us200-million-at-the-market-program-to-strengthen-the-companys-financial-position/
  62. https://www.canopygrowth.com/wp-content/uploads/2024/05/Q4-FY2024-MDA-FINAL.pdf
  63. https://www.prnewswire.com/news-releases/canopy-growth-announces-entry-of-tweed-brand-to-german-medical-cannabis-market-302386861.html
  64. https://www.canopygrowth.com/investors/news-releases/canopy-growth-announces-changes-to-global-operations-to-drive-strategic-focus/
  65. https://stockstotrade.com/news/canopy-growth-corporation-cgc-news-2025_08_25/
  66. https://www.businesswire.com/news/home/20250805318456/en/Canopy-Growth-Expands-Global-Medical-Portfolio-with-Launch-of-7ACRES-in-Australia
  67. https://obj.ca/canopy-growth-continues-global-expansion-with-southern-africa-acquisition/
  68. https://www.newcannabisventures.com/canopy-growth-provides-update-on-international-operations-and-activities/
  69. https://www.prnewswire.com/news-releases/canopy-growth-announces-changes-to-global-operations-to-drive-strategic-focus-301041965.html
  70. https://www.canopygrowth.com/brands/
  71. https://finance.yahoo.com/news/canopy-growth-expands-global-medical-113000821.html
  72. https://www.stocktitan.net/news/CGC/canopy-growth-announces-doja-as-dedicated-canadian-medical-ezatxisyrvrk.html
  73. https://stockanalysis.com/stocks/cgc/company/
  74. https://financialpost.com/pmn/business-wire-news-releases-pmn/canopy-growth-drives-innovation-in-high-demand-segments-with-latest-product-launches
  75. https://finance.yahoo.com/news/canopy-growth-launches-deep-space-113000719.html
  76. https://ir.cbrands.com/news-events/press-releases/detail/210/constellation-brands-to-acquire-minority-stake-in-canopy-growth-corporation
  77. https://www.newcannabisventures.com/canopy-growth-details-c245-million-constellation-brands-strategic-investment/
  78. https://ir.cbrands.com/news-events/press-releases/detail/205/constellation-brands-5-billion-cad-4-billion-usd-investment-in-canopy-growth-closes-following-shareholder-and-canadian-government-approval
  79. https://www.canopygrowth.com/investors/news-releases/constellation-brands-to-invest-5-billion-cad-4-billion-usd-in-canopy-growth-to-establish-transformative-global-position-and-alignment/
  80. https://ir.cbrands.com/news-events/press-releases/detail/85/constellation-brands-enters-into-agreement-with-canopy-growth-corporationto-modify-warrants-and-other-rights
  81. https://www.cbrands.com/blogs/press-releases/constellation-brands-announces-conversion-of-common-shares-and-exchange-of-promissory-note-into-exchangeable-shares-of-canopy-growth-corporation
  82. https://finimize.com/content/cgc-asset-snapshot
  83. https://www.fool.com/investing/2019/04/21/3-crazy-facts-about-canopy-growths-largest-acquisi.aspx
  84. https://www.canopygrowth.com/investors/news-releases/canopy-growth-and-acreage-confirm-canopy-usas-completed-acquisition-of-acreage/
  85. https://mjbizdaily.com/canopy-acquire-german-cannabis-company-c3-250-million/
  86. https://tracxn.com/d/acquisitions/acquisitions-by-canopy-growth/__twFb8TUw4VJBMW1-kIz7Ob3nxhMQFUUIqwXb1yMFmDs
  87. https://www.canopygrowth.com/investors/news-releases/canopy-growth-confirms-canopy-usas-exercise-of-options-to-acquire-wana-and-jetty/
  88. https://www.canopygrowth.com/investors/news-releases/canopy-growth-confirms-canopy-usas-acquisition-of-wana/
  89. https://www.greenhousegrower.com/management/leading-cannabis-grower-canopy-growth-expands-with-acquisition/
  90. https://www.prnewswire.com/news-releases/canopy-growth-announces-divestiture-of-canadian-retail-operations-301634641.html
  91. https://cassels.com/rep_work/canopy-announces-divestiture-of-canadian-retail-operations/
  92. https://www.prnewswire.com/news-releases/canopy-growth-announces-facility-sale-and-provides-update-on-divestiture-actions-301866870.html
  93. https://cassels.com/rep_work/canopy-growth-completes-sale-of-hershey-drive-facility/
  94. https://www.canopygrowth.com/investors/news-releases/canopy-growth-announces-completed-sale-of-this-works/
  95. https://www.macrotrends.net/stocks/charts/CGC/canopy-growth/revenue
  96. https://www.canopygrowth.com/wp-content/uploads/2022/06/Q4-FY22-MDA-FINAL.pdf
  97. https://www.macrotrends.net/stocks/charts/CGC/canopy-growth/income-after-taxes
  98. https://www.macrotrends.net/stocks/charts/CGC/canopy-growth/net-income-loss
  99. https://www.canopygrowth.com/investors/news-releases/canopy-growth-reports-first-quarter-fiscal-year-2025-financial-results/
  100. https://dcfmodeling.com/blogs/health/cgc-financial-health
  101. https://www.timothysykes.com/news/canopy-growth-corporation-cgc-news-2025_10_01/
  102. https://companiesmarketcap.com/canopy-growth/stock-price-history/
  103. https://mjbizdaily.com/canopy-growth-files-2-billion-preliminary-base-shelf-prospectus/
  104. https://www.canopygrowth.com/investors/news-releases/canopy-growth-announces-us750-million-term-loan-financing/
  105. https://www.canopygrowth.com/investors/news-releases/canopy-growth-announces-financing-to-further-strengthen-balance-sheet-including-approximately-us50-million-of-new-gross-proceeds/
  106. https://finance.yahoo.com/news/canopy-growth-strengthens-balance-sheet-110000173.html
  107. https://www.cannabisbusinesstimes.com/finance/news/15751799/canopy-growth-agrees-to-make-3-prepayments-to-reduce-term-loan-by-50-million
  108. https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cgc/canopy-growth
  109. https://www.prnewswire.com/news-releases/canopy-growth-reports-second-quarter-fiscal-year-2025-financial-results-302299610.html
  110. https://www.prnewswire.com/news-releases/canopy-growth-reports-third-quarter-fiscal-year-2025-financial-results-302370840.html
  111. https://www.canopygrowth.com/investors/news-releases/canopy-growth-reports-third-quarter-fiscal-2026-financial-results/
  112. https://www.canopygrowth.com/wp-content/uploads/2023/06/Q4-FY2023-FS-FINAL.pdf
  113. https://www.skadden.com/-/media/files/publications/2024/09/inside-the-courts/in-re-canopy-growth-sec-litig.pdf
  114. https://mjbizdaily.com/cannabis-giant-canopy-cites-spreadsheet-error-for-under-reporting-adjusted-ebitda/
  115. https://zlk.com/settlement/canopy-growth-corporation-settlement
  116. https://www.skadden.com/about/news-and-rankings/news/2024/07/canopy-growth-secures-dismissal-in-securities-fraud-class-action
  117. https://www.businesswire.com/news/home/20250602636057/en/Deadline-Soon-Canopy-Growth-Corporation-CGC-Investors-Who-Lost-Money-Urged-To-Contact-The-Law-Offices-of-Frank-R.-Cruz-About-Securities-Fraud-Lawsuit
  118. https://www.canopygrowth.com/wp-content/uploads/2025/07/2025.05.28-FINAL-CGC-Whistleblower-Policy.pdf
  119. https://www.canopygrowth.com/code-of-business-conduct-and-ethics/
  120. https://www.canopygrowth.com/wp-content/uploads/2021/09/Canopy-Growth-Corporation-Code-of-Conduct-and-Ethics-May-2021.pdf
  121. https://www.tipranks.com/stocks/cgc/risk-factors
  122. https://mjbizdaily.com/canopy-aphria-cited-for-critical-regulatory-breaches-in-2018/
  123. https://www.cannabisbusinesstimes.com/business-issues-benchmarks/compliance/news/15691913/canopy-growth-appeals-ca434611-fine-stemming-from-2019
  124. https://www.nasdaq.com/articles/canopy-growths-battle-against-unregulated-cannabis-rivals-threat-market-fairness-and
  125. https://www.canopygrowth.com/investors/news-releases/canopy-growth-us-cannabis-market/
  126. https://www.canopygrowth.com/wp-content/uploads/2025/08/CANOPY-GROWTH-CORP_AR_2025_V1.pdf
  127. https://www.sec.gov/Archives/edgar/data/1737927/000156459019032186/cgc-ex992_29.htm
  128. https://www.nsnews.com/national-business/canopy-growth-corp-appeals-cra-penalty-for-growing-pot-before-being-licensed-5194563
  129. https://leg.wa.gov/jlarc/reports/2025/CannabisMarket/pf_ii/default.html
  130. https://www.marketwatch.com/story/once-mighty-canopy-growth-loses-billions-as-dream-of-pot-riches-runs-into-reality-of-oversupply-and-overspending-83996ba9
  131. https://www.fool.ca/2025/09/03/these-threats-facing-canopy-growth-stock-could-justify-selling-it/
  132. https://mjbizdaily.com/canopy-growth-shuttering-facilities-across-canada-abandons-outdoor-cannabis-cultivation/
  133. https://seekingalpha.com/article/4466086-canopy-growth-corporation-cgc-ceo-david-klein-on-q3-2021-results-earnings-call-transcript
  134. https://www.youtube.com/watch?v=inKk4Ty0Xyc
  135. https://www.edgen.tech/news/stock/canopy-growth-navigates-financial-headwinds-amidst-us-market-ambitions
  136. https://www.ainvest.com/news/canopy-growth-corporation-stock-decline-structural-challenges-sector-tailwinds-2509/
  137. https://www.directorstalkinterviews.com/canopy-growth-corporation-cgc-stock-analysis-navigating-challenges-in-the-cannabis-sector/4121211968
Add your contribution
Related Hubs
User Avatar
No comments yet.